Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Humana is displaying robust revenue growth and expanding margins, driven by strong demand in core markets. Read more on why ...

This performance contributes to Humana’s impressive 10.1% revenue growth over the last twelve months, with the company generating a healthy 8% free cash flow yield.

This stock's P/B looks attractive against its industry's average P/B of 2.20. Within the past 52 weeks, HUM's P/B has been as high as 2.91 and as low as 1.52, with a median of 1.93.

This performance contributes to Humana’s impressive 10.1% revenue growth over the last twelve months, with the company generating a healthy 8% free cash flow yield. Strategic Initiatives and Growth ...

Today, Zacks Equity Research discusses The Cigna Group CI, Humana Inc. HUM, Centene Corp. CNC and Molina Healthcare, Inc. MOH ...

Centene's stock plunged after slashing 2025 EPS guidance due to higher-than-expected morbidity and lower market growth in key ...

The research firm’s maintained Neutral rating suggests a balanced view on Humana’s near-term performance prospects, with the $290.00 price target providing a benchmark for the stock’s valuation amid ...